neuroplasticity
(4)
Enspire DBS Therapy, Inc.
Enspire DBS Therapy is a Cleveland-based, clinical-stage medical device company commercializing deep brain stimulation (DBS) paired with physical rehabilitation to restore arm and hand function in people living with chronic impairment after a stroke. Spun out of Cleveland Clinic in 2010, the company builds on more than a decade of research targeting the brain's dentate nucleus to re-establish neurological input during rehab. Its DBS-plus-rehab approach showed encouraging results in the first-in-human EDEN trial published in Nature Medicine, and Enspire is now running RESTORE, a multicenter pivotal study aimed at FDA marketing authorization.
Constant Therapy
Constant Therapy is a Boston-area digital health company that turns speech, language, and cognitive rehabilitation into an AI-personalized app. Spun out of Boston University's Aphasia Research Laboratory in 2012, its platform delivers more than 100,000 evidence-based exercises across 80-plus task categories to people recovering from stroke, traumatic brain injury, aphasia, dementia, and other neurological conditions - and to the clinicians who treat them. A patented NeuroPerformance Engine adapts each session to the individual, extending therapy beyond the clinic and into daily home practice.
Scientific Learning, a Carnegie Learning Company
Scientific Learning, now part of Carnegie Learning, builds neuroscience-based reading and language software that rewires how struggling readers process language. Its flagship Fast ForWord program treats reading difficulty at its root - the brain's ability to process sound and sequence information - rather than drilling worksheets. Born from lab research by four scientists in 1996 and acquired by Carnegie Learning in 2020, the company has delivered cognitive-skills and reading interventions to students in more than 40 countries, backed by decades of peer-reviewed research.
Samphire Neuroscience
Samphire Neuroscience is a London-based neurotechnology company building drug-free, hormone-free wearables for women's health. Its flagship product, Nettle, is a headband that uses transcranial direct current stimulation (tDCS) to gently modulate the brain regions tied to mood and pain, worn 20 minutes a day in the run-up to menstruation. Marketed as the first EU-cleared (CE-certified) neuromodulation device for women's health, Nettle targets PMS, PMDD, menstrual pain and related hormonal conditions. Founded in 2021 by neuroscientist Emilė Radytė and IP lawyer Alex Cook, the company has raised roughly $7.77M across pre-seed, seed and Series A rounds.